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Abstract
Background: Cervical cancer (CC) occupies fourth place in cancer incidence and mortality worldwide in women,
with 560,505 new cases and 284,923 deaths per year. Approximately, nine of every ten (87%) take place in developing
countries. When a macroscopic nodal involvement is discovered during a radical hysterectomy (RH), there is
controversy in the literature between resect macroscopic lymph node compromise or abandonment of the
surgery and sending the patient for standard chemo-radiotherapy treatment. The objective of this study is to
compare the prognosis of patients with CC whom RH was abandoned and bilateral pelvic lymphadenectomy
and para-aortic lymphadenectomy was performed with that of patients who were only biopsied or with removal of a
suspicious lymph node, treated with concomitant radiotherapy/chemotherapy in the standard manner.
Methods: A descriptive and retrospective study was conducted in two institutions from Mexico and Colombia. Clinical
records of patients with early-stage CC programmed for RH with an intraoperative finding of pelvic lymph, para-aortic
nodes, or any extracervical involvement that contraindicates the continuation of surgery were obtained. Between
January 2007 and December 2012, 42 clinical patients complied with study inclusion criteria and were selected
for analysis.
Results: In patients with CC whom RH was abandoned due to lymph node affectation, there is no difference in
overall survival or in disease-free period between systematic lymphadenectomy and tumor removal or lymph
node biopsy, in pelvic lymph nodes as well as in para-aortic lymph nodes, when these patients receive adjuvant
treatment with concomitant radiotherapy/chemotherapy.
Conclusions: This is a hypothesis-generator study; thus, the recommendation is made to conduct randomized
prospective studies to procure better knowledge on the impact of bilateral pelvic and para-aortic
lymphadenectomy on this group of patients.
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Background
Cervical cancer (CC) occupies fourth place in cancer
incidence and mortality worldwide in women, with
560,505 new cases and 284,923 deaths per year. Ap-
proximately, nine of every ten (87%) of the latter take
place in developing countries [1]. In 2009, the Inter-
national Federation of Gynecology and Obstetrics
(FIGO) redefined CC staging, reiterating that this must
be clinical, to be more accessible to sectors and coun-
tries with low resources [2]. However, it must be con-
sidered that clinical staging entails a high percentage of
error, particularly in knowledge of the pelvic lymph
node and para-aortic involvement [3]. The National
Comprehensive Cancer Network (NCCN) recommends
radical hysterectomy (RH) with bilateral pelvic lymph-
adenectomy (BPL) for patients with CC in early stages
(IA2–IB1) and who do not wish to preserve fertility; in
the case of finding lymph node or extracervical spread
during the surgical approach, the RH should be sus-
pended, in order to carry out a pathological examin-
ation of the para-aortic lymph nodes and to administer
treatment with concomitant radiotherapy (RT) and
chemotherapy (ChemT) (RT/ChemT) [4]. The Gyneco-
logic Oncology Group (GOG) in 2000 published a
study where the main reason for suspending a RH in
patients with early stage CC was the presence of lymph
node involvement [5]. At present, studies have not
demonstrated the benefit of completing RH in the case
of trans-surgical findings of extra-cervix tumor spread
[6, 7]. However, para-aortic lymphadenectomy (PAL)
has the intent of surgical staging to establish the need
for extending radiation fields, although controversy
continues to exist concerning its usefulness in progno-
sis [8]. In addition, there is controversy in the literature
between resect macroscopic lymph node compromise
or abandonment of the surgery and sending the patient
for standard radical treatment.
The objective of this study is to compare the prognosis
of patients with CC whom RH was abandoned and BPL
and PAL was performed, with that of patients who were
only biopsied or with removal of a suspicious lymph
node, treated with concomitant RT/ChemT in the stand-
ard manner.
Methods
A descriptive and retrospective study was conducted in
two institutions from Mexico and Colombia. Clinical
records of patients with early stage CC programmed for
RH with an intraoperative finding of pelvic lymph,
para-aortic nodes, or any extracervical involvement that
contraindicates the continuation of surgery were ob-
tained. Patients with non-invasive CC, with any other
primary tumor, who were submitted to surgery after RT
and/or ChemT, or who had incomplete clinical records
were excluded from the study. The project was ap-
proved by the Ethics and Research Committees of the
Instituto Nacional de Cancerología (INCan) of Mexico
and Instituto de Cancerología de Las Américas (ICLA),
Medellin, Colombia.
The following variables were evaluated: country, age,
body mass index (BMI), histology, clinical stage, size of
the pathological tumor, presence of lymphovascular
space involvement (LVSI), histological grade, reason for
abandonment of surgery, type of lymphadenectomy or
tumor removal, surgical time, trans-surgical bleeding,
transfusion, presence of other complications related with
the surgical procedure, duration of definitive post-
surgical treatment, and type of recurrences.
BPL was defined as bilateral resection of all lymph
nodes between the circumflex vein as inferior margin,
2 cm above the external iliac-artery bifurcation as su-
perior margin, the genitocrural nerve as lateral margin,
the superior vesical artery as medial margin, and the
obturator nerve as dissection floor. With regard to
PAL, lateral margins were the ureters, the inferior mar-
gin was 2 cm above the external iliac-artery bifurcation,
and the superior margin at least to the inferior mesen-
teric artery. Tumor removal was defined as resection of
solely the macroscopic lymph node disease, and lymph
node biopsy (LNB), as taking a portion of the macro-
scopically affected lymph node. In data analysis, surgi-
cal procedures were not mutually exclusive. Surgical
time was defined as from skin incision to closing of the
latter. Complications related with the procedure were
those that presented during 7 days after the surgical
procedure.
After the procedure, all of the patients received de-
finitive treatment. Patients who had pelvic lymph node
affectation exclusively received concomitant ChemT/
RT and brachytherapy (BT) or external RT with BT ex-
clusively. In the case of para-aortic disease, extended
fields of the para-aortic region were included according
to guidelines established for this procedure. If there
was a disease in other organs, the patients received
platinum-based chemotherapy. Treatment duration was
defined as time between initiation of definitive onco-
logic treatment and finalization of the latter. Disease-
free period (DFP) in months was defined as time
between finalization of definitive treatment and pres-
ence of recurrence, the patient’s last visit, or last
follow-up. Overall survival (OS) in months was defined
as the period between diagnosis and the patient’s death
or last follow-up visit.
Descriptive statistics was carried out for demographic
variables, reporting central tendency medians. Univariate
analysis was performed by Mann–Whitney U test for
continuous variables, and the chi-squared or the Fisher
exact test according to the case for ordinal variables. In
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the case of its being feasible, the variables were included
in the multivariate Cox analysis. OS and DFP were ana-
lyzed by the Kaplan–Meier method, and curves were
compared utilizing the log-rank test. Statistical signifi-
cance was defined with a value of p <0.05. The IBM
SPSS statistical package for Mac (2013) was used.
Results
Between January 2007 and December 2012, 42 clinical
patients complied with study inclusion criteria and were
selected for analysis. Clinicopathological characteristics
are described in Table 1. Median age was 46 years (inter-
quartile range (IQR), 40.8–56), with a BMI of 25.7 (IQR,
23.2–29.5). Twenty (42.6%) patients were submitted to
some imaging study; of these, 10 (50%) had computed
tomography (CT), being the most frequently utilized
study for evaluation. The most common histology was
squamous cell in 24 (57.1%) cases, followed by adenocar-
cinoma in 12 (28.6%), adenosquamous in 4 (9.5%), and
other histologies in 2 cases (4.8%). In 37 (88.1%) cases,
initial clinical stage was IB1, with 2 (4.8%) in IB2 and
with 3 (7.1%) in IIA1. Median tumor size was 3.0 cm
(IQR, 2.0–4.0). Fourteen (33.3%) cases were well-
differentiated, 17 (40.1%) moderately differentiated, and
11 (26.2%) poorly differentiated. Only 5 (12%) patients
presented lymphovascular involvement.
The principal reason for not performing the RH was
the presence of lymph node disease in 28 (66.6%) pa-
tients, followed by parametrial involvement in 7 (16.7%)
patients, and due to other reasons in 7 (16.7%) patients.
Among patients in whom the reason was lymph node
involvement, pelvic lymph node disease was present in
19 (67.8%) cases, followed by para-aortic lymph nodes in
9 (32.2%) cases. Thirty-three (78.6%) patients were sub-
mitted to some type of surgical procedure on the pelvic
lymph nodes, and 20 (47.6%) patients had some type of
procedure on para-aortic lymph nodes. These proce-
dures were not mutually exclusive.
Of the 33 patients who had undergone some surgical
procedure in pelvic lymph nodes, 19 (57.6%) patients
underwent tumor removal or LNB and 14 (42.4%)
underwent BPL (Table 2). Median number of lymph
nodes obtained in the BPL group was 14 (IQR, 8–21). A
statistically significant difference was found in terms of
the institution of origin (p = 0.02), with a distribution in
the case of tumor removal or LNB of 10 (52.6%) patients
for INCan and 9 (47.4%) for ICLA, while in the case of
BPL, distribution was 2 (14.3%) and 12 (85.7%). A differ-
ence was also found with respect to BMI (p = 0.01), with
27.4 (IQR, 25.3–31.1) for patients who underwent tumor
removal or LNB vs. 24.6 (IQR, 22.4–25.4) for patients
submitted to BPL. Statistically significant differences
were not found in terms of age, histology, clinical stage,
tumor size, grade of tumor, presence of lymphovascular
space involvement, surgical time, amount of bleeding,
transfusions, other types of complications, hospital stay,
duration of definitive treatment, or presence of recur-
rences. Two surgically related complications were ob-
served: one hydroelectrolytic decompensation in the
BPL group and one pulmonary thromboembolism in the
Table 1 Clinical and pathological characteristic of patients with
cervical cancer with abandoned hysterectomy (N = 42)
Countrya
Mexico (INCan) 19 (45)
Colombia (ICLA) 23 (55)
Age (years)b 46 (40.8–56)
BMIb 25.68 (23.2–29.5)













Tumor size (cm)b 3.0 (2.0–4.0)
Tumor gradea
Well-differentiated 14 (33.3)
Moderately differentiated 17 (40.1)
Poorly differentiated 11 (26.2)
LVSIa 5 (12)
Reason for abandonmenta
Pelvic lymph node affectation 19 (45.2)
Para-aortic lymph node affectation 9 (21.4)








BMI body mass index, CT computed tomography, MRI magnetic resonance
imaging, LVSI lymphovascular space involvement
aN (relative frequency)
bMedian (interquartile range)
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tumor removal or LNB group, without this achieving a
statistically significant difference (p = 0.82).
Of patients on whom some para-aortic lymph node
procedure was performed, 14 (70%) had tumor removal
or LNB and 6 (30%) had PAL (Table 3). Median number
of lymph nodes obtained in the PAL procedure was 6
(IQR, 4–6). In the group of tumor removal or LNB, 6
(42.9%) cases had squamous histology and 5 (35.7%) of
adenocarcinoma, while in the PAL group, there were 3
(50%) cases of squamous and 3 (50%) of adenocarcinoma
(p = 0.021). Likewise, there was a difference (p < 0.001)
with respect to stages: in the tumor removal group, there
were 12 (85.7%) in stage IB1 and 2 (14.3%) in IB2, while
in the PAL group, there were 6 (100%) in IB1. In terms
of recurrence in para-aortic procedure group, 3 (21.4%)
regional and 3 (21.4%) distant metastasis were found in
the tumor removal or the para-aortic LNB group, and
only 1 (16.7%) local recurrence was observed in the PAL
group (p = 0.04). Regarding complications, only 1
(16.7%) patient presented hydroelectrolytic decompen-
sation, who was the same as reported in the compari-
son with BPL. With regard to the pathology report, in
the group of LNB or tumor removal, 6 (42.9%) patients
had lymph node metastasis, and in the PAL group,
there was 1 (16.7%) without a statistically significant
difference (p = 0.354). No statistically significant differ-
ence was observed in the remainder of the variables
analyzed.
Median follow-up was 32.2 months (range, 5.7–
93.8 months). In patients on whom some surgical
procedure involving pelvic lymph nodes had been per-
formed, 5-year OS in the tumor removal or LNB
group was 55.5 vs. 90.9% in the group with BPL,
without a statistically significant difference (p = 0.171)
(Fig. 1), while DFP was 52.0 vs. 60%, respectively,
without a statistically significant difference (p = 0.265)
(Fig. 2). In patients on whom a surgical procedure
was performed on para-aortic lymph nodes, 5-year
OS in the tumor removal or the LNB group was
42.1%, and 100% in the PAL group, without a signifi-
cant difference (p = 0.126) (Fig. 3), while 5-year DFP
was 32.5 and 80%, respectively, without a statistically
significant difference (p = 0.437) (Fig. 4).
Discussion
In early stages of CC, the probability of pelvic lymph
node metastasis is 2 to 8%, while para-aortic involve-
ment is extremely rare [9]. The most important prog-
nostic factor in these patients is lymph node disease: in
stages IB or IIA with negative pelvic lymph nodes, 5-
year OS is 88–96%, compared with 50–74% at similar
stages with metastasis to lymph nodes [10]. The results
are worse if there is para-aortic disease [11]. The main
cause for abandonment of RH is the trans-surgical
presence of affected lymph nodes. The GOG in the year
2000 analyzed patients with stage IB1 CC on whom HR
was abandoned. Of 1127 patients, 68 (8.7%) underwent
abandonment of their surgical procedure, finding that




N = 19 (57.6%)
Pelvic
lymphadenectomy
N = 14 (42.4%)
p
Countrya
Mexico (INCan) 10 (52.6) 2 (14.3) 0.02
Colombia (ICLA) 9 (47.4) 12 (85.7)
Age (years)b 45 (35-53) 45.5 (40-54.3) 0.55
BMI b 27.4 (25.3–31.1) 24.6 (22.4–25.4) 0.01
Histologya
Squamous 9 (47.4) 9 (64.3) 0.22
Adenocarcinoma 5 (26.3) 5 (35.7)
Adenosquamous 3 (15.8) 0
Others 2 (10.5) 0
Initial clinical stagea
IB1 18 (94.7) 13 (92.9) 0.82
IB2 1 (5.3) 1 (7.1)
Tumor size (cm)b 3 (1.6–4) 3 (2–4) 0.63
Tumor gradea
Well-differentiated 4 (21.1) 7 (50) 0.05
Moderately
differentiated
7 (36.8) 6 (42.9)
Poorly differentiated 8 (42.1) 1 (7.1)
LVSIa 3 (15.8) 2 (14.3) 0.74
Systematic PALa 1 (5.3) 5 (35.7) 0.062
BPRa 11 (57.9) 3 (21.4) 0.073
PR positive 17 (89.5) 12 (85.7) NS
Surgical time (min)b 150 (120–190) 165 (103.8–198.8) 0.69
Blood loss (mm)b 100 (70–250) 100 (57.5–212.5) 0.78
Blood transfusiona 1 (0.05) 1 (0.07) 0.82
Others complicationsa 1 (0.05) 1 (0.07) 0.82




10 (7.5–14) 8.8 (8.1–11) 0.57
Recurrencea 7 (26.8) 2 (14.3) 0.15
Local 1 (14.3) 0
Regional 6 (85.7) 2 (100)
Distance 0 0
Confidence interval 95%
BMI body mass index, Mod moderate, LVSI lymphovascular space involvement,
PAL para-aortic lymphadenectomy, BPR biopsy or pelvic lymph node removal,
PR pathology report, NS not significant
aN (relative frequency)
bMedian (interquartile range)
Barquet-Muñoz et al. World Journal of Surgical Oncology  (2017) 15:23 Page 4 of 9
the majority of these were due to lymph node metasta-
sis: in 25 patients by para-aortics and in 12 by pelvic
nodes [5]. In our study, the main cause for abandon-
ment of RH was the presence of lymph node disease in
66.6%. The majority was due to pelvic lymph nodes in
19 cases, in comparison with 9 cases with para-aortic
metastatic disease. It is important to consider that only
42.6% of patients had at least one imaging study prior
to the surgical procedure, with CT being the most fre-
quently utilized imaging study, and that in none of
these patients was there suspicion of tumor activity at
the lymph node level (Table 1). This is probably be-
cause, in early CC stages, management guidelines do
not recommend the performance of routine imaging
studies [4]. One must also consider that the sensitivity
and specificity of CT in diagnosing lymph node disease
ranges from 64.7 to 96.6% [12]. Finally, it is probable
that patients with results of lymph node suspicion were
never programmed for a surgical procedure, but were
instead sent to treatment with concomitant RT/
ChemT.
In the literature, there are studies that do not demon-
strate a benefit on completing RH in the case of finding
trans-surgical lymph node metastasis. In 2008, Richard
et al. compared two groups of patients obtained from
the Surveillance Epidemiology and End Results (SEER)
study with a diagnosis of stage IB1 CC and lymph node
metastasis; patients in the former group were submitted
to RH with BPL and PAL, and in patients in the latter
group, RH was aborted and only BPL and PAL were car-
ried out, both groups receiving adjuvant RT. With a
follow-up of more than 6 years, a difference was not
found in 5-year OS (69 vs. 71%; p = 0.45) and in death
due to disease (31 vs. 24%; p = 0.4), the treatment was
considered equivalent in both groups [6]. Gray et al. ana-
lyzed 268 women with CC with early stages, RH was not
completed in 7%; among these, the main reason was
macroscopic pelvic lymph node disease (84%), and in
the remainder other causes of extracervical disease. Of
the group in which RH was aborted, 17% recurred vs.
8% of patients on whom the surgery was completed
(p = 0.168). Likewise, a difference was not found in OS
in the group with abandoned RH vs. those on whom
RH was performed (73 vs. 80%; p = 0.772). A differ-
ence was also not found in the rate of surgical compli-
cations between both groups (10 vs. 11%; OR, 0.92;
95% CI, 0.08–6.633) [7]. However, Suprasert et al.
found a difference in the prognosis between to con-
tinue or to abandon the surgical procedure. These au-
thors found that although there was no significant
difference in the rate of complications of both groups,
a superior 2-year DFP was found in patients submit-
ted to RH in comparison with those on whom the
procedure was abandoned (93.5 vs. 58.5%; p = 0.01).




N = 14 (70.0%)
Para-aortic
lymphadenectomy
N = 6 (30.0%)
p
Countrya
Mexico (INCan) 5 (35.7) 2 (33.3) 0.26
Colombia (ICLA) 9 (64.3) 4 (66.7)
Age (years)b 45 (40–45) 44.5 (42–50) 0.90
BMIb 26.55 (23.7–28.3) 23.9 (22.5–32.7) 0.60
Histologya
Squamous 6 (42.9) 3 (50) 0.02
Adenocarcinoma
5 (35.7) 3 (50)
Adenosquamous
1 (7.1) 0
Others 2 (14.3) 0
Initial clinical stagea
IB1 12 (85.7) 6 (100) <0.001
IB2 2 (14.3) 0




4 (28.6) 3 (50) 0.95
Moderately
differentiated




LVSIa 3 (21.4) 0 0.09
PR positive 6 (42.9) 1 (16.7) 0.354
Surgical time
(min)b
172.5 (90–195) 120 (100–195) 0.78
Blood loss (mm)b 100 (70–300) 140 (100–250) 0.72
Blood transfusiona 0 0 NS
Others
complicationsa
0 1 (16.7) <0.001
Hospital stay
(days)b




10.5 (8.2–14.2) 10.5 (8–15.4) 0.66
Recurrencea
Local 0 1 (16.7) <0.001
Regional 3 (21.4) 0
Distance 3 (21.4) 0
Confidence interval 95%
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On the other hand, there were differences in the
amount of positive lymph nodes and in the amount of
patients who received extended-field RT [13].
A search was conducted in the literature that analyzes
the prognosis of carrying out systematic BPL in patients
with abandoned RH due to trans-surgical findings;
however, no publication was identified on this theme. In
our study, the performance of BPL vs. tumor removal or
LNB was compared, without finding a difference in OS
and DFP between the groups (Figs. 1, 2, 3, and 4). It
would appear that treatment with post-surgical RT or
concomitant ChemT/RT is sufficient without performing
Fig. 1 Overall survival (OS) in patients with pelvic lymph node procedure. Five-year OS in the LNB group was 55.5%, and in the BPL group
90.9% (p = 0.171)
Fig. 2 Disease-free survival (DFS) in patients with pelvic lymph node procedure. Five-year DFS in the LNB group was 52%, and in the BPL group
60% (p = 0.265)
Barquet-Muñoz et al. World Journal of Surgical Oncology  (2017) 15:23 Page 6 of 9
a more extensive surgical procedure. In addition, it is
noteworthy that median BMI was higher in patients of
the tumor removal or LNB group in comparison with
those of the BPL group (27.4 vs. 24.6; p = 0.01) and that
this could be why there are fewer patients on whom a
more extensive surgical procedure was performed.
Similarly, it appears that at INCan (14%), a lesser num-
ber of extensive procedures was performed in compari-
son with ICLA (86%); however, this type of decision can
be influenced by the higher BMI in the tumor removal
or LNB group. In terms of surgical time, bleeding, or
other complications, need for transfusions, hospital stay,
Fig. 3 Overall survival (OS) in patients with para-aortic lymph node procedure. Five-year OS in the LNB group was 42.1%, and in the PAL group
100% (p = 0.126)
Fig. 4 Disease-free survival (DFS) in patients with para-aortic lymph node procedure. Five-year DFS in the LNB group was 32.5%, and in the PAL
group 80% (p = 0.437)
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and treatment duration, there is no statistically significant
difference between the two groups. Although we would ex-
pect that a difference would exist clinically, absence of the
latter can be explained in part by our study’s sample size.
In our group of patients, there was no difference be-
tween OS and DFP in patients on whom PAL was per-
formed vs. tumor removal or LNB. This can be due to
that all patients received extended-field RT. In the
study of Varia and collaborators, 95 women with CC
and para-aortic affectation were treated with concomi-
tant ChemT/RT (extended-field), finding a 3-year OS
and a 3-year DFP of 39 and 34%, respectively, and grade
3 or greater toxicity rate of 19%, suggesting that control
of the disease can be achieved with this modality [14].
In our series of patients on whom PAL was carried out,
no patients presented lymph node recurrence, but these
patients did present a higher rate of trans-surgical com-
plications, in contrast with those only submitted to
tumor removal or LNB. These results must be regarded
with a certain reservation due to the limited number of
cases; however, this did suggest that patients not sub-
mitted to PAL can present microscopic tumor activity
and that this can be the cause of para-aortic recurrence.
The role of PAL in patients with lymph node affliction
remains controversial. In the study of Lai and coworkers,
the authors analyzed the advantage of performing PAL on
patients with CC in comparison with carrying out imaging
studies, finding longer OS (p = 0.024) and shorter DFP
(p = 0.003) in the group of surgical patients [15]. In the
study of Chantalat et al., a difference in OS was not
found between patients who had been submitted to
PAL and those who not (p = 0.31) [16].
To our knowledge, this is the first study to evaluate
the role of BPL, in particular in patients whose HR sur-
gical procedure was abandoned because of suspicion of
lymph node affectation. These results should be taken
with reserve. Among the study’s limitations, we find its
retrospective characteristics, the short follow-up, the
upper limit of PAL is not known, and few patients have
been evaluated, in addition to that the ChemT or RT
type of definitive treatment and its duration or initiation
can differ between the two participating institutions.
Conclusions
In patients with CC on whom RH was abandoned due to
lymph node affectation, there is no difference in OS or in
DFP between systematic lymphadenectomy vs. tumor re-
moval or LNB, in pelvic lymph nodes as well as in para-
aortic lymph nodes, when these patients receive adjuvant
treatment with concomitant RT/ChemT. This is a
hypothesis-generator study; thus, the recommendation is
made to conduct randomized prospective studies to pro-
cure better knowledge on the impact of BPL and PAL on
this group of patients.
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